LCI Lannett Co., Inc.
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Philadelphia, PA.
Company profile
Ticker
LCI
Exchange
Website
CEO
Timothy C. Crew
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
IRS number
230787699
LCI stock data
()
Calendar
7 May 20
4 Jul 20
30 Jun 21
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 144.37M | 136.11M | 127.34M | 133.84M | |
| Net income | -16.59M | 5.08M | -12.16M | -7.59M | |
| Diluted EPS | -0.43 | 0.13 | -0.32 | -0.2 | |
| Net profit margin | -11.49% | 3.74% | -9.55% | -5.67% | |
| Operating income | -2.09M | 16.78M | 9.4M | 9.4M | |
| Net change in cash | -17.72M | 18.17M | -39.24M | -64.96M | |
| Cash on hand | 101.46M | 119.18M | 101.01M | 140.25M | |
| Cost of revenue |
| Annual (USD) | Jun 19 | Jun 18 | Jun 17 | Jun 16 | |
|---|---|---|---|---|---|
| Revenue | 655.41M | 684.56M | 633.34M | 542.49M | |
| Net income | -272.11M | 28.69M | -547K | 44.86M | |
| Diluted EPS | -7.2 | 0.75 | -0.02 | 1.2 | |
| Net profit margin | -41.52% | 4.19% | -0.09% | 8.27% | |
| Operating income | -262.32M | 129.7M | 86.45M | 130.76M | |
| Net change in cash | 41.66M | -19.15M | -107.03M | 24.43M | |
| Cash on hand | 140.25M | 98.59M | 117.74M | 224.77M | |
| Cost of revenue |
Financial data from Lannett earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 1 Jul 20 | Landis G. Michael | Common Stock | Payment of exercise | Dispose F | No | 7.07 | 392 | 2.77K | 37,294 |
| 19 May 20 | Drabik David A | Common Stock | Sell | Dispose S | No | 7.37 | 37,220 | 274.31K | 45,972 |
| 19 May 20 | Taveira Paul | Common Stock | Sell | Dispose S | No | 7.22 | 30,000 | 216.6K | 51,415 |
| 12 May 20 | Crew Timothy C | Common stock | Buy | Aquire P | Yes | 7.57 | 3,000 | 22.71K | 190,738 |
| 7 May 20 | Cavanaugh Maureen | Common Stock | Payment of exercise | Dispose F | No | 7.58 | 2,384 | 18.07K | 61,589 |
| 31 Mar 20 | Crew Timothy C | Common stock | Other | Aquire J | No | 5.91 | 1,171 | 6.92K | 187,738 |
Institutional ownership Q1 2020
90.8% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 149 |
| Opened positions | 14 |
| Closed positions | 35 |
| Increased positions | 53 |
| Reduced positions | 47 |
13F shares |
Current |
|---|---|
| Total value | 1.48B |
| Total shares | 36.64M |
| Total puts | 831.5K |
| Total calls | 376.4K |
| Total put/call ratio | 2.2 |
Largest owners |
Shares | Value |
|---|---|---|
| Telemus Capital | 7.69M | $58.84M |
| BLK BlackRock | 5.16M | $35.89M |
| JPM JPMorgan Chase & Co. | 3M | $20.85M |
| D. E. Shaw & Co. | 2.66M | $18.48M |
| Vanguard | 2.19M | $15.26M |
| LSV Asset Management | 2.12M | $14.71M |
| STT State Street | 1.31M | $9.1M |
| Renaissance Technologies | 1.09M | $7.55M |
| Dimensional Fund Advisors | 802.26K | $5.58M |
| IVZ Invesco | 691.61K | $4.81M |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absenteeism, adhere, Aid, alternative, Amantadine, argue, attendance, attention, carefully, carryback, CDC, Chancery, check, China, cleaning, combat, combating, confidence, criteria, cybersecurity, deductibility, deemed, deferral, detrimental, discouraging, disease, distancing, divert, duration, emerged, enclosing, encountered, enhanced, epidemic, essential, evolving, experienced, experiencing, floor, fogging, foregoing, formal, HCL, HCTZ, healthcare, HIV, hold, home, hygiene, inability, incident, instability, instance, intact, interruption, job, joinder, jointly, LIBOR, lifted, lockdown, London, magnitude, Memorandum, monitor, network, Organization, outbreak, outlook, Oxycodone, pandemic, physician, Pilocarpine, political, powered, precautionary, prospect, public, quarantine, rapidly, refile, relief, reluctant, remote, remotely, respirator, retirement, rubber, sanitizing, screening, show, shut, situation, social, sort, speed, spread, strain, suspended, temporarily, thermal, travel, Triamterence, undergo, Understanding, underway, unknown, vendor, voluntary, weekly, widespread, worldwide, Wuhan
Financial reports
10-Q
2020 Q3
Quarterly report
7 May 20
10-Q
2020 Q2
Quarterly report
6 Feb 20
10-Q
2020 Q1
Quarterly report
7 Nov 19
10-K
2019 FY
Annual report
28 Aug 19
10-Q
2019 Q3
Quarterly report
7 May 19
10-Q
2019 Q2
Quarterly report
7 Feb 19
10-Q
2019 Q1
Quarterly report
8 Nov 18
10-K
2018 FY
Annual report
28 Aug 18
10-Q
2018 Q3
Quarterly report
8 May 18
10-Q
2018 Q2
Quarterly report
8 Feb 18
Current reports
8-K
Entry into a Material Definitive Agreement
10 Jun 20
8-K
Lannett Announces Fiscal 2020 Third-quarter Financial Results
7 May 20
8-K
Lannett Announces Fiscal 2020 Second-quarter Financial Results
7 Feb 20
8-K
Submission of Matters to a Vote of Security Holders
24 Jan 20
8-K
Entry into a Material Definitive Agreement
26 Nov 19
8-K
Lannett Announces Fiscal 2020 First-quarter Financial Results
8 Nov 19
8-K
Other Events
31 Oct 19
8-K
Lannett Announces Closing of $86.25 Million of Convertible Senior Notes Due 2026
27 Sep 19
8-K
Lannett Announces Pricing of $75 Million of Convertible Senior Notes Due 2026
25 Sep 19
8-K
INVESTOR PRESENTATION September 2019 © 2019 Lannett Company, Inc. All Rights Reserved. For Discussion Purposes Only
24 Sep 19
Registration and prospectus
S-3
Shelf registration
20 Dec 19
S-8
Registration of securities for employees
22 Mar 19
S-3ASR
Automatic shelf registration
13 Feb 18
S-3ASR
Automatic shelf registration
12 May 17
S-8
Registration of securities for employees
23 Jan 14
25
Voluntary exchange delisting
12 Dec 13
8-A12B
Registration of securities on exchange
2 Dec 13
424B5
Prospectus supplement for primary offering
4 Oct 13
FWP
Free writing prospectus
4 Oct 13
424B5
Prospectus supplement for primary offering
3 Oct 13
Proxies
DEF 14A
Definitive proxy
6 Dec 19
DEFA14A
Additional proxy soliciting materials
21 Dec 18
DEF 14A
Definitive proxy
10 Dec 18
DEF 14A
Definitive proxy
7 Dec 17
DEF 14A
Definitive proxy
12 Dec 16
DEF 14A
Definitive proxy
8 Dec 15
PRE 14A
Preliminary proxy
27 Nov 15
DEF 14A
Definitive proxy
16 Dec 14
DEF 14A
Definitive proxy
17 Dec 13
PRE 14A
Preliminary proxy
6 Dec 13
Other
EFFECT
Notice of effectiveness
27 Jan 20
CORRESP
Correspondence with SEC
21 Jan 20
CORRESP
Correspondence with SEC
9 Jan 20
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
26 Apr 17
CORRESP
Correspondence with SEC
29 Mar 17
UPLOAD
Letter from SEC
16 Mar 17
CORRESP
Correspondence with SEC
7 Mar 17
UPLOAD
Letter from SEC
23 Feb 17
UPLOAD
Letter from SEC
11 Mar 16
Ownership
4
LANNETT / G. Michael Landis ownership change
2 Jul 20
4
LANNETT / David A Drabik ownership change
21 May 20
4
LANNETT / Paul Taveira ownership change
21 May 20
4
LANNETT / Timothy C Crew ownership change
13 May 20
4
LANNETT / Maureen Cavanaugh ownership change
8 May 20
4
LANNETT / John Abt ownership change
1 May 20
SC 13G/A
Lannett Co Inc
14 Feb 20
SC 13G
Beneficial ownership report
11 Feb 20
SC 13G
Beneficial ownership report
11 Feb 20
SC 13G/A
Lannett Co Inc
4 Feb 20